We Create
We help birth novel therapies to reduce patient suffering and improve health.
Learn moreWe help birth novel therapies to reduce patient suffering and improve health.
Learn moreWe deliver safer and more effective life-saving treaments.
Learn moreOur flagship solution, miniPRO™ proteins, enable drug hunters to deliver safer and more effective treatments in a fraction of the time of traditional discovery methods.
Learn moreOrdaōs miniPRO™ proteins provide the power and performance of antibodies, but are configurable, more stable, and easier to scale-up and manufacture. These proteins are 20x smaller than traditional monoclonal antibodies enabling them to more easily penetrate and effectively treat disease microenvironments.
The Ordaōs Design Engine generates, appraises, and ranks billions of protein sequences, hundreds of thousands of protein structures and properties to create miniPRO™, our de novo class of mini-proteins.
Learn moreThe Ordaōs Design Engine is a generative perception engine that leverages reinforcement learning and proprietary data sets to translate human-targeted product criteria into machine-designed mini-proteins. The design engine produces proteins that are more therapeutically effective, less likely to cause adverse side effects, and are easier and less expensive to develop, test, and manufacture than traditional proteins.
By maximizing drug candidate delivery speed, novelty, and probability of clinical success, we can provide the highest client confidence in every investigational new drug (IND) application.
What’s more, our clients see a return on their investment in weeks, rather than months or years.
See our latest newsFailure rate of drug discovery.
Drug development lifecycles.
Cost of each new drug released to market.
We are a human-enabled, machine-driven drug design company that creates bespoke mini-proteins to help pharma and biotechs around the world deliver safer and more effective life-saving treatments in a fraction of the time of traditional discovery methods.
Our deep learning approach goes beyond rational combinatorial methods. We leverage a generative perception engine powered by reinforcement learning and proprietary data sets to translate human-targeted product criteria into machine-designed mini-proteins.
By maximizing drug candidate delivery speed, novelty, and probability of clinical success, we can provide the highest client confidence in every investigational new drug (IND) application. What’s more, our clients see a return on their investment in weeks, rather than months or years.